Key result
Non-invasive evaluation of endothelial function demonstrates that accumulation of coronary risk factors impairs flow-mediated dilatation, whereas long-term hormone replacement therapy improves it.
Why the study?
Impairment of vascular endothelial function is the initial step in atherosclerosis development, and the long-term effects of estrogen therapy on endothelial function in postmenopausal women are not well reported.
Does reduced-dose estrogen therapy improve endothelial function in postmenopausal women?
Does reduced-dose estrogen therapy improve endothelial function in postmenopausal women?
Reduced-dose estrogen therapy may be sufficient to improve endothelial function in postmenopausal women.
Answers are grounded in this paper and cite their sources.
Reduced-dose HRT may improve endothelial function in postmenopausal women; leaves open clinical outcome benefits.
Evidence has accumulated that impairment of vascular endothelial function is the initial step in the development of atherosclerosis. One important finding is impairment of the release of endothelium-dependent relaxing factor, which is now thought to be nitric oxide or its related substances, from endothelial cells. Flow-mediated dilatation has been known to be endothelium-dependent, and this can be detected during reactive hyperemia by high-resolution ultrasound in superficial arteries. Several coronary risk factors have been reported to be significantly related with decreased flow-mediated dilatation. We studied the association between the accumulation of coronary risk factors (hyperlipidemia, diabetes mellitus, hypertension, and current smoking habitus) and vascular endothelial function. The lower incidence of atherosclerosis in women before the menopause than that in men is an established epidemiological observation. Short-term estrogen therapy improves endothelial function in postmenopausal women. However, there are few reports on its long-term effects on endothelial function. Furthermore, we determined whether a reduced dosage of estrogen may maintain its beneficial effects. A similar improvement was also observed while women were on hormone replacement therapy even at the reduced dosage. Our results indicate that even at half the dose of estrogen, hormone replacement therapy may improve endothelial function in postmenopausal women.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2003) conducted a review in Endothelial dysfunction. Hormone replacement therapy and coronary risk factors was evaluated on Flow-mediated dilatation (FMD). Non-invasive evaluation of endothelial function demonstrates that accumulation of coronary risk factors impairs flow-mediated dilatation, whereas long-term hormone replacement therapy improves it.
Synapse has enriched 10 related papers. Consider them for comparative context: